Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients

Respiration

Volumn 85, Issue 2, 2013, Pages 119-125

  Zhao, Xiao ^a   Han, Ru Bing ^a   Zhao, Jing ^a   Wang, Jun ^b   Yang, Fan ^b   Zhong, Wei ^a   Zhang, Li ^a   Li, Long Yun ^a   Wang, Meng Zhao ^a,c  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c NONE   (China)

Author keywords

Epidermal growth factor receptor; Mutation; Non small cell lung cancer; Plasma

Indexed keywords

CELL DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CELL FREE SYSTEM; COMPARATIVE STUDY; EARLY CANCER; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PLASMA; PLASMA CHARACTERISTICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; AMINO ACID SEQUENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DNA EXTRACTION; ENZYME BLOOD LEVEL; ENZYME TISSUE LEVEL; HUMAN TISSUE; MUTATION RATE; NON SMALL CELL LUNG CANCER; TISSUE LEVEL;

EID: 84874114196     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000338790     Document Type: Article

References (26)

1. Lynch TJ, Bell DW, Sordella R, Gurubhaga-vatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to ge-f itinib. N Engl J Med 2004; 350: 2129-2139.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
3. Wojas-Krawczyk K, Krawczyk P, Mlak R, Kucharczyk T, Kowalski DM, Krzakowski M, Milanowski J: The applicability of a predictive index for second-and third-line treatment of unselected non-small-cell lung cancer patients. Respiration 2011; 82: 341-350.
4. Costa DB, Kobayashi S, Tenen DG, Huber-man MS: Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58: 95-103.
5. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, An-nessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G, Lodi R, Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A, Del Pozo N, Rosell R, Guijarro R, Galbis J, Sanchez JJ, Camps C, Ye L, Ma GH, Chen L, Li M, Liu JL, Yang K, Li QY, Li N, Wan HY: Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer quantification of circulating cell-free DNA in the serum of patients with obstructive sleep apnea-hypop-nea syndrome. Lung Cancer 2009; 64:92-97.
6. Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A, Del Pozo N, Rosell R, Guijarro R, Galbis J, Sanchez JJ, Camps C: Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6:286-290.
7. Ye L, Ma GH, Chen L, Li M, Liu JL, Yang K, Li QY, Li N, Wan HY: Quantification of circulating cell-free DNA in the serum of patients with obstructive sleep apnea-hypop-nea sy ndrome. Lung 2010; 188: 469-474.
8. Jahr S, Hentze H, Englisch S, Hardt D, Fack-elmayer FO, Hesch RD, Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61:1659-1665.
9. Kimura H, Kasahara K, Kawaishi M, Kuni-toh H, Tamura T, Holloway B, Nishio K: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006; 12: 3915-3921.
10. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-2501.
11. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-8923.
12. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duf-field EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
13. Maemondo M, Inoue A, Kobayashi K, Suga-wara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated egfr. N Engl J Med 2010; 362:2380-2388.
14. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, You C: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multi-centre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735-742.
15. Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, Hiraki A, Sugi K, Kiura K, Date H, Shimizu N: Detection of EGFR gene mutation in lung cancer by muta nt-enriched polymerase chain reaction assay. Clinical Cancer Res 2006; 12:43-48.
16. Sobin LH, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumors, ed 7. Oxford, Wiley-Blackwell, 2009.
17. Moran MT, Sanchez JM, Isla D, Cobo M, Paz-Ares L, Catot S, Jimenez U, Diz P, Taron M, Rosell R: High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients (P) with poor performance status (PS). J Thorac Oncol 2007; 2:S444.
18. Ren J, Song GH, Zhang LJ, Di LJ, Yuan YH, Yu J, Jia J: Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. Chin J Cancer Res 2010; 22:27-31.
19. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel RJ, Janne PA: Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009; 15:2630-2636.
20. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 2653-2659.
21. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M: Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012; 7:115-121.
22. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S: Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007; 97:778-784.
23. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM: Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15:2076-2084.
24. Brevet M, Johnson ML, Azzoli CG, Ladanyi M: Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011; 73: 96-102.
25. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J: Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009; 125: 2393-2399.
26. Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita T, Ichikawa Y, Waseda Y, Watanabe K, Shiarasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, Tamura T, Nishio K, Fujimura M, Nakao S: EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006; 1: 260-267.